Bactolife secures USD 5 million in new financing

The financing will be used to accelerate the use of its technology platform that develops binding proteins for gut infections. Globally, there are more than 1.6 billion cases of diarrheal diseases annually, which at best means stomach upsets. At worst, they can lead to life-threatening illnesses. This investment will help develop a new biologic solution reducing the risk of gut infections in both humans and animals.